Efficacy and safety of tranilast combined with minocycline in the treatment of moderate-to-severe rosacea: a prospective, randomized controlled study.
Jingchen Liang, Ying Chen, Mengyao Yang et al.
✦ AI-curated · Sources linked
In 30 seconds
This prospective randomized controlled study evaluated tranilast, minocycline, and their combination in patients with moderate-to-severe rosacea. Forty-five patients completed 12 weeks of treatment. At week 12, the combination group had a higher IGA success rate (93.33%) than the tranilast (53.33%) and minocycline (46.67%) groups (p < 0.05). Measures of facial erythema also favored combination therapy over minocycline alone. The abstract reports no serious adverse events among patients treated with tranilast.
Key findings
- At week 12, IGA success was 93.33% with combination therapy, 53.33% with tranilast, and 46.67% with minocycline (p < 0.05).
- CEA success rate, erythema index, and erythema score favored combination therapy over minocycline (p = 0.021, 0.030, and 0.024, respectively).
- The study reports no serious adverse events in patients treated with tranilast.
Why it matters
The findings suggest that adding tranilast to minocycline may improve clinical response and facial erythema outcomes in moderate-to-severe rosacea compared with minocycline alone. The randomized comparison provides preliminary clinical evidence for this combination, while the small number of study completers means the results should be interpreted cautiously.
What to keep in mind
Only 45 patients completed the study, and follow-up was limited to 12 weeks.